An investigation of cut-points for primary breast cancer oestrogen and progesterone receptor assays

Journal of Steroid Biochemistry and Molecular Biology

Volumn 57, Issue 5-6, 1996, Pages 323-328

  Chapman, J W ^a,c   Mobbs, B G ^a,c   McCready, D R ^a,c   Lickley, H L A ^a,c   Trudeau, M E ^a,c   Hanna, W ^a,c   Kahn, H J ^a,c   Sawka, C A ^b,c   Fish, E B ^a,c   Pritchard, K I ^b,c  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MULTIVARIATE ANALYSIS; PROGNOSIS; QUANTITATIVE ASSAY; RECEPTOR DENSITY;

EID: 0030012881     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-0760(95)00275-8     Document Type: Article

References (26)

1. Cohen J. L., Raam S. and Gelman R.: A blinded study of inter- and intra-laboratory variations in the performance of estrogen receptor (ER) assay. In Estrogen Receptor Assays in Breast Cancer, Laboratory Discrepancies and Quality Assurance. (Edited by G. J. Sarfaty, A. R. Nash and D. D. Keightley) Masson Publishing, New York (1981) pp. 43-56.
2. Ryan E. D., Clark A. F., Mobbs B. G., Ooi T. C., Sutherland D. J. A. and Tustanoff E. R.: Inter-laboratory quality control of estrogen and progesterone receptor assays in breast cancer tissue using lyophilised cytosols. Clin. Biochem. 18 (1985) 20-26.
3. Mobbs B. G., Chapman J. W., Sutherland D. J. A., Ryan E., Tustanoff E. R., Ooi T. C. and Narasimha Murthy P. V.: Evidence for bimodal distribution of breast carcinoma ER and PgR values quantitated by enzymeimmunoassay. Eur. J. Cancer 29A (9) (1993) 1293-1297.
4. Cren H., Lechevrel C., Roussel G. and Goussard J.: Evolution of immunoreactivity of monoclonal antibodies H222 and/or D547 used in the detection of breast cancer estrogen receptors. Varying reactivity of receptor isoforms. J. Steroid Biochem. Molec. Biol. 39 (1991) 519-527.
5. Chapman J. W., Mobbs B. G., Hanna W. M., Sawka C. A., Pritchard K. I., Lickley H. L. A., Trudeau M. E., Ryan E. D., Ooi T. C., Sutherland D. J. A., Tustanoff E. R. and McCready D. R.: The standardization of estrogen receptors. J. Steroid Biochem. Molec. Biol. 45(5) (1993) 367-373.
6. Walt A. J., Singhakowinta A., Brooks S. C., et al.: The surgical implications of estrophile protein estimations in carcinoma of the breast. Surgery 50 (1976) 506-512.
7. Knight WA III, Livingstone R. B., Gregory E. J. and McGuire W. L.: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 37 (1977) 4669-4671.
8. Cooke T., George D., Shields R., Maynard P. and Griffiths K.: Oestrogen receptors and prognosis in early breast cancer. Lancet 1 (1979) 995-997.
9. Allegra J. C., Lippman M. E. and Simon R.: Association between steroid hormone receptor status and disease free interval in breast cancer. Cancer Treat. Rep. 63 (1979) 1271-1277.
10. Blarney R. W., Bishop H. M., Blacke J. R. S., Doyle P. J., Elston C. W., Haybittle J. L., Nicholson R. I. and Griffiths K.: Relationship between primary breast tumour receptor status and patient survival. Cancer 46 (1980) 2765-2769.
11. Stewart J. F., Rubens R. D., Millis R. R., King R. J. B. and Hayward J. L.: Steroid receptors and prognosis in operable (stage I and II) breast cancer. Eur. J. Cancer Clin. Oncol. 19 (1983) 1381-1387.
12. Howell A., Barnes D. M. and Harland R. N. L.: Steroid hormone receptors and survival after first relapse in breast cancer. Lancet 1 (1984) 588-591.
13. Hilf R., Feldstein M. L., Gibson S. L., and Savlov E. D.: The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy for women with breast cancer. Cancer 45 (1980) 1993-2000.
14. Clark G. M., McGuire W. L., Hubay C. A., Pearson O. H. and Marshall J. S.: Progesterone receptors as a prognostic factor in stage II breast cancer. N. Engl. J. Med. 309 (1983) 1343-1347.
15. Thorpe S. M., Rose C., Rasmussen B. B., Mouridsen H. T., Bayer T. and Keiding N. on behalf of the Danish Breast Cancer Cooperative Group: Prognostic value of steroid hormone receptors: Multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res. 47 (1987) 6126-6133.
16. McGuire W. L.: Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Sem. Oncol. 5 (1978) 428-433.
17. Keshgegian A. A.: Erb B-2 oncoprotein overexpression in breast carcinoma: Inverse correlation with biochemically- and immunohistochemically-determined hormone receptors. Breast Cancer Res. Treat. 35 (1995) 201-210.
18. Fuqua S. A., Allred D. C. and Auchus R. J.: Expression of estrogen receptor variants. J. Cell Biochem. Suppl. 17G (1993) 194-197.
19. Altman D. G., Lausen B. and Sauerbrei W.: Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J. Natl. Cancer Inst. 86(11) (1994) 829-835.
20. Hanna W., McCready D. R., Chapman J. W., Mobbs B. G. and Trudeau M. E.: The predictive value of ERICA in breast cancer recurrence: a univariate and multivariate analysis. Mod. Pathol. 6(6) (1993) 748-754.
21. Murray D., Chapman J. W., Trudeau M. E., Pritchard K. I., Hanna W. M., Kahn H. J., McCready D. R. and Lickley H. L. A.: Towards a standardized clinical cutpoint for flow cytometry in node negative breast cancer. Proc. Am. Ass. Cancer Res. 34 (1993) 192. (Abstr.)
22. Chapman J. W., Murray D., Trudeau M. E., Pritchard K. I., Hanna W., Kahn H. J., Sawka C. A., McCready D. R., Demianiuk C., Fish E. B., Hitchcock C. L. and Lickley H. L. A.: Optimal DNA index in a flow cytometry investigation of node negative breast cancer. Proc. Am. Ass. Cancer Res. 36 (1995). (Abstr.)
23. Chapman J. W., Mobbs B. G., McCready D. R., Lickley H. L. A., Trudeau M. E., Hanna W., Kahn H. J., Sawka C. A. and Pritchard K. I.: Estrogen and progesterone receptor assay cut-points for primary breast cancer. Proc. Am. Ass. Cancer Res. 35 (1994) 228. (Abstr.)
24. Mobbs B. G. and Johnson I. E.: Use of an enzymeimmunoassay (EIA) for quantitation of cytosolic and nuclear estrogen receptor, and correlation with progesterone receptor in human breast cancer. J. Steroid Biochem. 28(6) (1987) 653-662.
25. Chapman J. W., Trudeau M. E., Pritchard K. I., Sawka C. A., Mobbs B. G., Hanna W. M., Kahn H., McCready D. R. and Lickley H. L. A.: A comparison of all subset Cox and accelerated failure time models with Cox step-wise regression for node positive breast cancer. Breast Cancer Res. Treat. 22(3) (1992) 263-272.
26. Godolphin W., Elwood J. M. and Spinelli J. J.: Estrogen receptor quantitation and staging as complementary prognostic indicators in breast cancer. A study of 583 patients. Int. J. Cancer 28 (1981) 677-683.